Crispr Therapeutics Ag Stock Price History
| CRSP Stock | USD 41.22 0.05 0.12% |
Below is the normalized historical share price chart for Crispr Therapeutics AG extending back to October 19, 2016. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Crispr Therapeutics stands at 41.22, as last reported on the 22nd of March, with the highest price reaching 41.68 and the lowest price hitting 40.41 during the day.
If you're considering investing in Crispr Stock, it is important to understand the factors that can impact its price. Currently, Crispr Therapeutics AG is very steady. Crispr Therapeutics secures Sharpe Ratio (or Efficiency) of 0.0255, which signifies that the company had a 0.0255 % return per unit of risk over the last 3 months. We have found twenty-three technical indicators for Crispr Therapeutics AG, which you can use to evaluate the volatility of the firm. Please confirm Crispr Therapeutics' Standard Deviation of 3.59, risk adjusted performance of (0.01), and Mean Deviation of 2.64 to double-check if the risk estimate we provide is consistent with the expected return of 0.0913%.
As of 03/22/2025, Other Stockholder Equity is likely to grow to about 3.5 B, while Total Stockholder Equity is likely to drop slightly above 1.1 B. . At this time, Crispr Therapeutics' Price Book Value Ratio is relatively stable compared to the past year. As of 03/22/2025, Price To Book Ratio is likely to grow to 1.80, though Price Earnings To Growth Ratio is likely to grow to (0.07). Crispr Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 19th of October 2016 | 200 Day MA 48.3349 | 50 Day MA 42.9128 | Beta 1.762 |
Crispr |
Sharpe Ratio = 0.0255
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | CRSP | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 3.58 actual daily | 31 69% of assets are more volatile |
Expected Return
| 0.09 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Crispr Therapeutics is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Crispr Therapeutics by adding it to a well-diversified portfolio.
Price Book 1.8277 | Enterprise Value Ebitda 14.1584 | Price Sales 94.6384 | Shares Float 84.3 M | Wall Street Target Price 83.6 |
Crispr Therapeutics Stock Price History Chart
There are several ways to analyze Crispr Stock price data. The simplest method is using a basic Crispr candlestick price chart, which shows Crispr Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | February 19, 2025 | 53.02 |
| Lowest Price | January 14, 2025 | 38.36 |
Crispr Therapeutics March 22, 2025 Stock Price Synopsis
Various analyses of Crispr Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Crispr Stock. It can be used to describe the percentage change in the price of Crispr Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Crispr Stock.| Crispr Therapeutics Price Action Indicator | 0.20 | |
| Crispr Therapeutics Price Rate Of Daily Change | 1.00 | |
| Crispr Therapeutics Accumulation Distribution | 46,910 | |
| Crispr Therapeutics Price Daily Balance Of Power | 0.04 |
Crispr Therapeutics March 22, 2025 Stock Price Analysis
Crispr Stock Price History Data
The price series of Crispr Therapeutics for the period between Sun, Dec 22, 2024 and Sat, Mar 22, 2025 has a statistical range of 14.66 with a coefficient of variation of 7.01. The prices are distributed with arithmetic mean of 42.59. The median price for the last 90 days is 41.99. The company had 333333:100 stock split on 19th of July 2016.| Open | High | Low | Close | Volume | ||
| 03/21/2025 | 40.71 | 41.68 | 40.41 | 41.22 | 1,539,519 | |
| 03/20/2025 | 41.23 | 42.50 | 41.03 | 41.17 | 1,115,939 | |
| 03/19/2025 | 41.20 | 42.75 | 40.70 | 41.94 | 1,243,267 | |
| 03/18/2025 | 42.67 | 42.67 | 40.40 | 40.97 | 1,932,909 | |
| 03/17/2025 | 41.94 | 43.32 | 41.46 | 42.82 | 1,131,393 | |
| 03/14/2025 | 42.55 | 43.48 | 41.94 | 42.12 | 1,423,319 | |
| 03/13/2025 | 43.20 | 44.39 | 41.63 | 41.99 | 1,193,234 | |
| 03/12/2025 | 42.64 | 43.94 | 42.42 | 43.49 | 1,399,805 | |
| 03/11/2025 | 42.93 | 43.34 | 40.82 | 42.37 | 1,979,439 | |
| 03/10/2025 | 44.67 | 46.07 | 42.78 | 43.34 | 2,925,237 | |
| 03/07/2025 | 42.88 | 45.79 | 42.48 | 45.53 | 1,885,440 | |
| 03/06/2025 | 42.57 | 43.74 | 41.53 | 43.31 | 1,275,855 | |
| 03/05/2025 | 43.50 | 44.35 | 42.35 | 43.84 | 1,187,042 | |
| 03/04/2025 | 40.73 | 44.32 | 40.52 | 43.45 | 2,114,705 | |
| 03/03/2025 | 45.16 | 45.20 | 42.10 | 42.29 | 1,725,314 | |
| 02/28/2025 | 42.62 | 44.51 | 42.00 | 43.92 | 1,659,625 | |
| 02/27/2025 | 44.57 | 46.78 | 43.51 | 43.62 | 1,481,786 | |
| 02/26/2025 | 44.88 | 46.00 | 43.97 | 44.40 | 1,238,343 | |
| 02/25/2025 | 46.23 | 46.67 | 44.02 | 44.51 | 2,156,679 | |
| 02/24/2025 | 46.69 | 47.66 | 45.10 | 46.57 | 2,197,819 | |
| 02/21/2025 | 51.23 | 51.47 | 47.34 | 47.91 | 2,672,207 | |
| 02/20/2025 | 52.58 | 52.77 | 49.22 | 50.43 | 2,974,052 | |
| 02/19/2025 | 52.40 | 55.88 | 52.23 | 53.02 | 4,765,793 | |
| 02/18/2025 | 52.25 | 55.30 | 51.02 | 52.22 | 6,024,470 | |
| 02/14/2025 | 46.21 | 52.60 | 46.04 | 49.72 | 7,737,500 | |
| 02/13/2025 | 43.70 | 44.14 | 42.20 | 43.49 | 2,049,171 | |
| 02/12/2025 | 40.67 | 44.20 | 40.50 | 43.30 | 4,241,378 | |
| 02/11/2025 | 39.01 | 39.72 | 38.28 | 39.62 | 2,027,435 | |
| 02/10/2025 | 40.00 | 40.04 | 39.18 | 39.41 | 1,418,401 | |
| 02/07/2025 | 41.00 | 41.74 | 39.35 | 39.71 | 2,168,267 | |
| 02/06/2025 | 42.71 | 42.88 | 40.54 | 40.61 | 1,592,748 | |
| 02/05/2025 | 40.79 | 42.60 | 40.53 | 42.22 | 1,842,844 | |
| 02/04/2025 | 40.00 | 41.11 | 39.75 | 40.49 | 1,507,110 | |
| 02/03/2025 | 40.19 | 41.10 | 39.21 | 40.00 | 2,234,888 | |
| 01/31/2025 | 42.15 | 43.00 | 41.42 | 41.59 | 2,038,805 | |
| 01/30/2025 | 41.59 | 42.89 | 41.28 | 42.04 | 1,630,274 | |
| 01/29/2025 | 41.85 | 42.94 | 40.79 | 41.21 | 1,311,707 | |
| 01/28/2025 | 41.93 | 42.39 | 40.94 | 41.81 | 1,425,238 | |
| 01/27/2025 | 41.94 | 42.86 | 41.14 | 41.85 | 1,715,277 | |
| 01/24/2025 | 44.58 | 45.10 | 43.00 | 43.42 | 2,275,485 | |
| 01/23/2025 | 43.61 | 44.49 | 42.43 | 44.23 | 2,493,125 | |
| 01/22/2025 | 41.65 | 45.77 | 41.19 | 44.20 | 5,393,771 | |
| 01/21/2025 | 41.44 | 42.44 | 40.90 | 41.51 | 1,813,932 | |
| 01/17/2025 | 41.00 | 41.55 | 40.45 | 40.53 | 1,387,300 | |
| 01/16/2025 | 39.76 | 40.68 | 39.44 | 40.30 | 1,613,634 | |
| 01/15/2025 | 39.88 | 40.99 | 38.89 | 39.04 | 1,753,847 | |
| 01/14/2025 | 39.62 | 40.20 | 38.21 | 38.36 | 1,489,215 | |
| 01/13/2025 | 39.06 | 39.20 | 36.52 | 38.85 | 2,748,433 | |
| 01/10/2025 | 40.04 | 40.37 | 38.51 | 39.69 | 2,408,540 | |
| 01/08/2025 | 41.56 | 41.73 | 40.55 | 41.29 | 982,408 | |
| 01/07/2025 | 42.92 | 44.12 | 41.66 | 41.92 | 1,525,580 | |
| 01/06/2025 | 41.25 | 44.28 | 41.21 | 42.43 | 2,430,324 | |
| 01/03/2025 | 41.50 | 42.09 | 40.70 | 41.02 | 1,445,617 | |
| 01/02/2025 | 39.81 | 41.44 | 39.34 | 41.43 | 1,662,593 | |
| 12/31/2024 | 39.00 | 39.69 | 38.75 | 39.36 | 1,661,938 | |
| 12/30/2024 | 39.55 | 39.67 | 38.20 | 38.65 | 2,189,153 | |
| 12/27/2024 | 40.76 | 41.14 | 39.85 | 40.02 | 1,665,944 | |
| 12/26/2024 | 40.21 | 41.34 | 40.00 | 41.07 | 1,149,591 | |
| 12/24/2024 | 40.48 | 41.02 | 39.80 | 40.94 | 759,865 | |
| 12/23/2024 | 40.82 | 40.84 | 39.77 | 40.48 | 1,516,756 | |
| 12/20/2024 | 40.25 | 41.02 | 39.41 | 40.72 | 3,348,387 |
About Crispr Therapeutics Stock history
Crispr Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Crispr is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Crispr Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Crispr Therapeutics stock prices may prove useful in developing a viable investing in Crispr Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 84.4 M | 60.3 M | |
| Net Loss | -585.2 M | -555.9 M |
Crispr Therapeutics Quarterly Net Working Capital |
|
Crispr Therapeutics Stock Technical Analysis
Crispr Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Global Markets Map Now
Global Markets MapGet a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
| All Next | Launch Module |
Crispr Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Crispr Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Crispr Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Crispr to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | 0.1964 | |||
| Treynor Ratio | (0.1) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Crispr Stock Analysis
When running Crispr Therapeutics' price analysis, check to measure Crispr Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Crispr Therapeutics is operating at the current time. Most of Crispr Therapeutics' value examination focuses on studying past and present price action to predict the probability of Crispr Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Crispr Therapeutics' price. Additionally, you may evaluate how the addition of Crispr Therapeutics to your portfolios can decrease your overall portfolio volatility.